Alcidion’s Share Price Lifts on UK Dartford and Gravesham Deal
19/03/2019
By Ryan Clarkson-Ledward
After being selected as a solution partner for Dartford and Gravesham NHS Trust in the UK — a contract valued at $2.1 million — Alcidion Group Ltd [ASX:ALC] shares are reflecting the good news.
At time of writing, Alcidion’s share price is trading at $0.055, gaining 3.77% on top of yesterday’s 12.50%.
A spike in share price following such a contract with capital growing potential shouldn’t come as a surprise to investors. It takes more than noticing whether a stock moves higher or lower to be a successful investor — otherwise anyone could be an expert stock picker.
Ideally, shareholders want a stock with the best chance of rising gradually over time…
The last five years has seen ALC’s share price yo-yo, which for a small-cap stock isn’t all that unusual as it takes time for stock to establish itself — particularly for a software company working in healthcare.
ALC has three healthcare software companies: Alcidion Corporation, Patientrack and Smartpage, and MKM Health.
Alcidion’s share price benefits from Miya platform
After winning the contract with Dartford and Gravesham, ALC will implement its Miya Platform along with its Smartpage and Patientrack in all wards within the Trust.
‘Miya Precision is a health analytics platform that solves clinical problems through provision of clinical decision support based on the application of algorithms, artificial intelligence and meaningful notifications’, as reported in yesterday’s announcement.
Commenting on the contract was Alcidion’s managing Director, Kate Quirke, saying:
‘This is a major win for Alcidion. Although the company has strong presence in the UK with Patientrack, this is the first integrated installation of the complete product platform — Miya Precision and Smartpage — outside of Australia.’
Meanwhile, Alcidion’s UK general manager Donald Kennedy said Alcidion was delighted to be partnering with Dartford and Gravesham, naming ALC as an important reference site as one of the pioneers of using real-time data and mobile devices in order to improve patient safety.
Dartford and Gravesham reflected ALC’s excitement, with Associate Director of Digital Transformation Neil Perry agreeing with the long-term benefits of the partnership. Perry stated:
‘Following a competitive tender process, we are very pleased to be working with Alcidion to implement its leading products suite across our hospitals.
‘Alcidion’s solutions are the right fit to help us meet our commitment to use digital technology to improve patient outcomes and shares these improvements with other NHS Trusts. Alcidion is a long-term solution partner for the Trust, and we believe its technology can empower our clinical staff to make informed decisions and focus on what they do best — deliver excellent patient care. We are very excited by the possibility in the use of artificial intelligence and natural language processing offered by the Alcidion solution.’
Alcidion’s outlook lends UK market growth
The last five years has seen ALC’s share price yo-yo, but Alcidion Group’s contract with Trust is set to change that, as it introduces new technology solutions in the UK market.
‘This contract is solid proof that we can effectively leverage our reputation and relationship in the UK and introduce an innovative new technology solution to the UK market,’ Kate Quirke said.
What’s more, branching outside of Australia and into the UK market sets Alcidion up for further global potential for its products. With the ever-increasing move towards technology and innovation avenues, in its abilities to provide care and actionable insight into patient conditions, the usefulness of Miya Precision implementation is looking very positive to both the company’s share price and investors.
With over 2,000 stocks on the ASX, creating a strong income portfolio can be difficult for everyday investors. In fact, many investors simply don’t know where to begin. That’s exactly why in Matt Hibbard’s latest special dividend report, he shares with you his five best dividend buys for 2019.
Download this free report now and discover:
The top five dividend paying stocks (you’ve almost certainly never heard of). Matt runs you through all the risks, rewards and reasons why these five ASX-listed stocks could form the next generation of Aussie income super stars.
Why the old rules of income investing DON’T apply anymore.If you think piling your money into Commonwealth Bank and Telstra is the best income strategy for your retirement nest egg. Think again! Matt shows you not only how the rules of income investing have changed, but explains why you can’t rely on the same old dividend payers anymore.
Why shaking up your income portfolio could be the smartest move you make in 2019. Make no mistake, while Matt still thinks that mega-cap stocks like ANZ or BHP will ‘likely play a part in many income portfolios’…this could be the perfect chance for savvy investors to boost their income portfolio for 2019 and beyond.
To download your free report ‘Top Five Dividend Stocks for 2019’ simply subscribe to Money Morning for FREE today. Enter your email in the box below and click ‘Send My Free Report’.
We will collect and handle personal information in accordance with our Privacy Policy.
Ryan Clarkson-Ledward
Ryan Clarkson-Ledward is one of Money Morning’s junior analysts. Ryan holds degrees in both communication and international business. He helps bring Money Morning readers the latest market updates, both locally and abroad. Ryan tackles all the issues investors need to know about that the mainstream media neglects. Ryan’s primary focus is assisting Sam Volkering with background research and insight for readers by dissecting the latest events affecting the world. Working closely with Sam, they explore the latest in small-cap and technology stocks as well as cryptocurrency opportunities. You can find Ryan’s contributing research, developments, and supporting information across several e-letters, including:
With over 2,000 stocks on the ASX, creating a strong income portfolio can be difficult for everyday investors. In fact, many investors simply don’t know where to begin. That’s exactly why in Matt Hibbard’s latest special dividend report, he shares with you his five best dividend buys for 2019.
